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HyperlipidemiaLipoprotein lipase (LPL) has been highly conserved through vertebrate evolution, making it challenging to
generate useful antibodies. Some polyclonal antibodies against LPL have turned out to be nonspeciﬁc, and the
availablemonoclonal antibodies (Mabs) against LPL, all ofwhich bind to LPL's carboxyl terminus, havedrawbacks
for some purposes. We report a new LPL-speciﬁc monoclonal antibody, Mab 4-1a, which binds to the amino
terminus of LPL (residues 5–25). Mab 4-1a binds human and bovine LPL avidly; it does not inhibit LPL catalytic
activity nor does it interfere with the binding of LPL to heparin. Mab 4-1a does not bind to human hepatic lipase.
Mab 4-1a binds to GPIHBP1-bound LPL and does not interfere with the ability of the LPL–GPIHBP1 complex to
bind triglyceride-rich lipoproteins.Mab4-1awill be a useful reagent for both biochemists and clinical laboratories.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Lipoprotein lipase (LPL) is a crucial enzyme for the hydrolysis of
triglycerides in plasma lipoproteins [1–3]. LPL is synthesized by adipo-
cytes and myocytes and secreted into the interstitial spaces. The LPL is
then picked up by GPIHBP1 (a glycosylphosphatidylinositol-anchored
protein of capillary endothelial cells) and shuttled to the luminal face
of capillaries. In the absence of GPIHBP1, LPL remains in the interstitial
spaces around adipocytes and myocytes and never reaches its site of
action within the capillary lumen [4]. A recent study by Gin and co-
workers [5] suggested that the GPIHBP1–LPL complex may be crucial
for the binding of triglyceride-rich lipoproteins (TRLs) to endothelial
cells [5]. TRLs bound to the LPL–GPIHBP1 complex on the cell surface
but not toGPIHBP1 alone [5]. GPIHBP1 and LPL are essential for the lipo-
lytic processing of TRLs. A deﬁciency of either protein results in severe
hypertriglyceridemia (chylomicronemia) [6,7] and impairs the delivery
of lipid nutrients to parenchymal cells [8,9].nal Science, Cornell University,
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. This is an open access article underLPL is a key player in human plasma triglyceride metabolism, but
studies of LPL biochemistry and function have been hampered by a
paucity of antibody reagents. LPL is highly conserved in vertebrates,
making it challenging to generate antibodies [10]. Widely used poly-
clonal antibodies against LPL have proven to be nonspeciﬁc [11]. Two
mouse monoclonal antibodies (Mabs) against bovine LPL, 5D2 and 5F9
[12–14], have been widely used. Both bind to the carboxyl-terminal
portion of bovine LPL and cross-react with human LPL (hLPL) [13].
Mab 5D2 has been useful for measurements of LPL mass [12,15], but it
is not suitable for some studies because it blocks the catalytic activity
of LPL [12,14]. Mab 5F9 binds to denatured human LPL but only weakly
to native LPL [13].
Here, we report a new mouse monoclonal antibody against hLPL,
4-1a. Mab 4-1a binds to the amino terminus of LPL, does not inhibit
catalytic activity, and binds avidly to GPIHBP1-bound LPL.
2. Material and methods
2.1. Lipase puriﬁcation
Human lipoprotein lipase (hLPL) for the immunization of mice was
puriﬁed from post-heparin human plasma [16]. The hLPL used to charac-
terize Mab 4-1a was produced in suspension cultures of Chinese hamster
ovary (CHO) cells and partially puriﬁed by heparin-Sepharose chroma-
tography. The concentration of hLPL was measured with a sandwichthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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was produced in suspension cultures of stably transfected CHO-Lec1
cells and puriﬁed by ceramic hydroxyapatite, heparin-Sepharose, and
Superdex 200 chromatography. The concentration of mLPL was mea-
sured with an ELISA [17]. Chicken LPL (cLPL) was puriﬁed from chicken
adipose tissue [18], and the concentration of cLPL was measured with
an ELISA [19]. Bovine LPL (bLPL) was puriﬁed from fresh milk [20] by
heparin-Sepharose, CHT hydroxyapatite, and Superdex 200 chromatog-
raphy. LPL catalytic activity was determined with a [3H]triolein sub-
strate [21]. Human hepatic lipase (hHL) was prepared from CHO-K1
cells that had been transiently transfectedwith a hHL expression vector,
pγk5-hHL, provided by Dr. Shau-Feng Chang (Heinrich-Pette-Institut,
Hamburg, Germany). hHL was puriﬁed by heparin-Sepharose chroma-
tography, and hHL mass was measured with an ELISA [22].2.2. Monoclonal antibody production
Mice were immunized with hLPL, and hybridomas were selected
after fusing splenocytes with myeloma cell line P3X [16,23]. The cells
were plated on 96-well plates with mouse peritoneal macrophages.
Ten days later, aliquots of the medium were tested for hLPL antibodies
with an ELISA. 96-well plates were coated with hLPL (5 ng/well), and
samples of the conditioned medium (100 μl) were added to the wellsFig. 1. Characterization of Mab 4-1a binding to LPL. A, Mab 4-1a binding to puriﬁed lipases in a
each sample,we added Laemmli buffer that had been spikedwith internalmolecularweight stan
loading control). The presence of the 4-1a antibody was detected with an IRDye800-labeled d
bovine serum albumin; bLPL, bovine LPL puriﬁed from milk; hLPL, human LPL puriﬁed from h
LPL from chicken adipose tissue; hHL, humanhepatic lipase. B, Binding ofMab4-1a to protein ex
vector or a mutant hLPL vector containing deletions of amino acids 51–298, 5–35, or 5–50. We
Binding of Mab 4-1a (red) or 5D2 (green) to wild-type hLPL or mutant hLPLs containing del
(green) to wild-type hLPL and mutant hLPLs containing Q3A and R4G mutations, and to wild-
of Mab 4-1a (green) or the V5 Mab (red) to culture supernatants from CHO cells transfected
or I8T mutations. On the right, binding of Mab 4-1a (red) and the V5 Mab (green) to culture s
and wild-type hLPL. The control lane shows nontransfected CHO cells. F, Binding of Mab 4-1a
with a wild-type hLPL vector or a mutant hLPL vector with a D9N mutation. G, Amino acid seq
residues are indicated by an asterisk.and incubated overnight. Mab binding was detected with an anti-mouse
IgG coupled to horseradish peroxidase. One hybridoma, 4-1a, produced
an antibody that bound hLPL; it was cloned twice by limiting dilution
and grown in serum-free media (Gibco PFHM-II) in CELLine Two-
Compartment Bioreactors (Wilsom Wolf). The isotype of Mab 4-1a
was IgG2a (Pierce Rapid Isotyping Kit). Mab 4-1a was puriﬁed on pro-
tein G-Sepharose columns (GE Healthcare); gel ﬁltration revealed a
single IgG peak.2.3. Characterization of Mab 4-1a
Binding of Mab 4-1a to puriﬁed preparations of LPL and HL was
assessed by western blotting. To localize the epitope for Mab 4-1a,
CHO cells were transiently transfected with expression vectors for V5-
tagged wild-type and mutant versions of hLPL and mLPL. Mutant LPLs
were created by site-directed mutagenesis using the QuikChange Light-
ning Site-Directed Mutagenesis kit (Stratagene). After 48 h, western
blotswere performed on cell extracts (or conditionedmedium samples)
with Mab 4-1a and either Mab 5D2 or a V5 Mab. Antibody binding was
detected with an Odyssey infrared scanner (Li-Cor).
Binding of Mab 4-1a to hLPL was also assessed with an ELISA.
96-well plateswere coatedwithMab 4-1a (1–3 μg/well), and the plates
were blocked with Superblock (Pierce) for 2 h at room temperature.western blot assay (350 ng/lane, as determined with an ELISA speciﬁc for each lipase). To
dards (37 and 50 kDa) labeledwith aﬂuorophore absorbing at 700 nm(white; serving as a
onkey anti-mouse IgG (black). Signals were detected with a Li-Cor infrared scanner. BSA,
LPL-transfected CHO cells; mLPL, mouse LPL puriﬁed from CHO-Lec1 cells; cLPL, chicken
tracts prepared fromCHO cells that had been transfectedwith awild-type hLPL expression
stern blots were performed with Mab 4-1a (green) or with an anti-V5 antibody (red). C,
etions of amino acids 5–15, 16–25, or 26–35. D, Binding of Mab 4-1a (red) or a V5 Mab
type mLPL and mutant mLPLs containing A3Q and G4R mutations. E, On the left, binding
with either a wild-type hLPL expression vector or mutant hLPL constructs containing I8S
upernatants of cells that had been transfected with mLPL-S8I, wild-type mLPL, hLPL-I8S,
(red) and Mab 5D2 (green) to culture supernatants from cells that had been transfected
uence alignment for the ﬁrst 25 amino acids of mature human and mouse LPL. Conserved
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60min)was added to thewells and incubated overnight. After washing
the plates with PBS/0.05% Tween-20, biotinylatedMab 5D2 [13], or bio-
tinylated Mab 4-1a was added and incubated for 5 h at room tempera-
ture. After washing the wells, NeutrAvidin–horseradish peroxidase
(ThermoScientiﬁc) was added and incubated for 30 min at 20 °C.
Color was developed with O-phenylenediamine dihydrochloride.
To test the ability of Mab 4-1a to bind GPIHBP1-bound LPL on the
surface of cells, CHO cells were transfected with empty vector, an
S-protein–tagged GPIHBP1 expression vector, or a mutant GPIHBP1
expression vector containing a C65S mutation (which abolishes the
ability of GPIHBP1 to bind LPL). One day later, the cells were washed
and incubated with hLPL at 4 °C. After 2 h, the cells were washed and
incubated with Mab 4-1a conjugated to Alexa-488 (Life Technologies)
for 1 h. The cells were then ﬁxed with 3% paraformaldehyde. GPIHBP1
was detected with a rabbit anti-S-protein antibody (Abcam) followed
byanAlexa-568–conjugated donkey anti-rabbit IgG (Life Technologies).Fig. 2. Properties of Mab 4-1a. A, Assessing effects ofMabs 4-1a and 5D2 on the catalytic activity
hLPL, and LPL catalytic activity was determined for 15minwith a [3H]triolein substrate [21]. The
to detect hLPL homodimers. Plates were coatedwithMab 4-1a orMab 5D2 (1 μg/well) and incu
atedMab 4-1a (ﬁlled circles) or biotinylatedMab 5D2 (open circles). C, Testing the ability of nat
Bound hLPL (50 ng/well) was detected with biotinylated Mab 5D2 and NeutrAvidin–horserad
Simultaneously, LPL catalytic activity was measured. Heat exposure inhibited LPL activity. Poin
speciﬁc activity of the substrate was 67,571 cpm/μmol fatty acid; the catalytic activity at t =
was immobilized on 96-well plates. Each well was coated with Mab 4-1a (1 μg/well). 220 ng o
to the immobilized Mab 4-1a was detected with Mab 5D2 as described earlier. E, Assessing th
was coated with heparin (25 μg/well). hLPL (1.1 μg) was pre-incubated with increasing am
heparin-coated wells and incubated overnight at 4 °C. After washing the plate with PBS/0.05%
mination of the afﬁnity of Mab 4-1a for hLPL. Plates were coated with 300 ng/well of Mab 4-1a
wells and incubated overnight. hLPLwas detectedwith biotinylated 5D2;mLPLwas detectedwi
as described in the Material and Methods.To determine if Mab 4-1a interfereswith the binding of TRLs to the LPL–
GPIHBP1 complex on the surface of cells, CHL cells expressing S-
protein–tagged GPIHBP1 were plated on coverslips in 24-well plates.
Cells were then incubated at 4 °C for 2 h with V5-tagged hLPL. After
washing, the cells were incubated with Mab 5D2, Mab 4-1a, or a V5-
speciﬁc Mab (Life Technologies) for 1 h. After washing, the cells were
then incubated with DiI-labeled TRLs (d b 1.006 g/ml lipoproteins
from Gpihbp1−/−mice) for 1 h [5], ﬁxed in 3% paraformaldehyde, and
blocked in 10% donkey serum. GPIHBP1 was detected with a rabbit
anti-S-protein antibody (Abcam) followed by an Alexa-488–conjugated
donkey anti-rabbit IgG (Life Technologies), and LPL–Mab complexes
were detected with an Alexa-647 conjugated donkey anti-mouse IgG
(Life Technologies). Images were obtained with an Axiovert 200 MOT
microscope (Zeiss) with 63×/1.25 oil immersion objective and proc-
essed with AxioVision 4.2 software (Zeiss).
To test the utility of Mab 4-1a to detect LPL in immunohistochemistry
studies, skeletal muscles from a wild-type mouse and a hLPL transgenicof hLPL. 30 μg ofMab 4-1a,Mab 5D2, or mouse IgG (mIgG, Sigma)was added to 0.25 μg of
results are the average of 4 independentmeasurements. B, Testing the ability of Mab 4-1a
bated overnightwith hLPL (0–200 ng/well). The captured LPL was detectedwith biotinyl-
ive and heat-denatured LPL to bind toMab 4-1a (3 μg/well) immobilized on 96-well plates.
ish peroxidase. Points showmeans of triplicates; variability between wells averaged 4.2%.
ts depict duplicate measurements of LPL catalytic activity; duplicates varied by b9%. The
0 was 41.6 μmol/h/ml. D, Effect of NaCl molarity on the binding of hLPL to Mab 4-1a that
f hLPL was added to wells in different concentrations of NaCl (0.15–1.5 M). hLPL binding
e effect of Mab 4-1a on the binding of hLPL to heparin-coated 96-well plates. Each well
ounts of Mab 4-1a or a control mouse IgG (Sigma) for 30 min and then added to the
Tween-20, hLPL bound to the immobilized heparin was detected with Mab 5D2. F, Deter-
or control mouse IgG for 48 h at 4 °C. After blocking the wells, hLPL or mLPL was added to
th a biotinylated goat anti-mouse LPL. TheKd ofMab 4-1a for hLPL andmLPLwas calculated
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prepared for immunohistochemistrywith theMouse onMouse (M.O.M.)
immunodetection kit (Vector Laboratories). Brieﬂy, methanol/acetone
ﬁxed sections (8–10-μm)were incubatedwith a ratmonoclonal antibody
against mouse GPIHBP1 (11A12) andMab 4-1a (5 μg/ml each), follow-
ed by an incubation with an Alexa-568 conjugated donkey anti-rat
IgG (1:200) and the M.O.M. biotinylated anti-mouse IgG reagent
(1:200). The sections were then incubated with Alexa-488–conjugated
avidin. The sections were then post-ﬁxed with 4% paraformaldehyde
and mounted on coverslips with DAPI antifade (Life Technologies).
To measure the Kd of hLPL and mLPL for Mab 4-1a, microtiter plates
were coatedwithMab 4-1a ormouse IgG (300 ng/well) for 48 h at 4 °C.
The plates were blocked with 5% bovine serum albumin, 0.05% Tween-
20 in phosphate buffered saline for 4 h. hLPL or mLPL (0–400 ng/well)
were added to wells and incubated overnight at 4 °C. The plates were
washed 9 times with PBS/0.05% Tween-20 and biotinylated Mab 5D2
(for human LPL) or biotinylated goat anti-mouse LPL (for mouse LPL)
were added to wells for an overnight incubation. After washing wells
extensively, NeutrAvidin horseradish peroxidase conjugate (Thermo
Scientiﬁc) was added to wells and incubated for 30 min at 20 °C. After
washing the wells and adding O-phenylenediamine substrate, the
OD490 nm was read after a 20-min incubation in the dark. The boundFig. 3. Assessing the ability of Mab 4-1a to bind to GPIHBP1-bound LPL on the surface of CHO
GPIHBP1 expression vector (middle two rows), or a mutant GPIHBP1 expression vector (C65S
with hLPL at 4 °C. 2 h later, the cells were washed and incubated with Mab 4-1a conjugated
protein tag antibody followed by an Alexa-568-labeled donkey anti-rabbit antibody (red) to dLPL mass was determined from standard curves for hLPL and mLPL. To
correct for non-speciﬁc binding, the values obtained for wells coated
with control mouse IgG were subtracted from the values from wells
coated with Mab 4-1a. The Kd was calculated using the least-squared
ﬁtting program in GraphPad Prism.
3. Results
The reactivity of Mab 4-1a with puriﬁed lipase preparations was
assessed with western blots. Mab 4-1a bound avidly to hLPL and bLPL
but weakly to mLPL and cLPL (Fig. 1A). There was no binding of Mab
4-1a to hHL (Fig. 1A). The epitope of Mab 4-1a was localized by
assessing the binding of Mab 4-1a to wild-type and mutant versions of
hLPL and mLPL. Mab 4-1a bound avidly to wild-type hLPL and a hLPL
mutant lacking residues 51–298 (hLPL-Δ[51–298]), but Mab 4-1a did
not bind to hLPL-Δ[5–35] or hLPL-Δ[5–50] (Fig. 1B). Further studies
showed that Mab 4-1a binds to hLPL-Δ[26–35] but not to hLPL-
Δ[5–15] or hLPL-Δ[16–25] (Fig. 1C), demonstrating that Mab 4-1a
binds within the ﬁrst 25 amino acids of hLPL. Because Mab 4-1a binds
weakly to mLPL, we compared the amino-terminal sequences of mLPL
and hLPL and found that they differed at three amino acid residues (res-
idues 3, 4, and 8 of hLPL; Fig. 1G). Changing amino acid residues 3 and 4cells. CHO cells were transfected with empty vector (top row), or an S-protein–tagged
) that cannot bind LPL (bottom row). One day later, the cells were washed and incubated
to Alexa-488 for 1 h. Washed cells were ﬁxed and then incubated with a rabbit anti-S-
etect GPIHBP1. DNA was stained with DAPI (blue).
Fig. 4.Mab 4-1a does not interfere with the binding of DiI-labeled TRLs to LPL–GPIHBP1 complexes on the surface of cells. CHL cells were transfected with empty vector or a mouse
GPIHBP1 expression vector. After 24 h, the cells were washed and incubated with V5-tagged hLPL, followed by incubations with Mab 4-1a, Mab 5D2, or a V5-speciﬁc Mab, and then by
an incubation with DiI-labeled TRLs (red). After washing the cells, the cells were ﬁxed. GPIHBP1 (green) was detected with a rabbit anti-S-protein antibody followed by an Alexa-488-
labeled donkey anti-rabbit antibody. The binding of Mab 4-1a, Mab 5D2, or the V5-Mab was detected with an Alexa-647-labeled donkey anti-mouse IgG (purple). DNA was stained
with DAPI (blue).
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minimal effects onMab 4-1a binding to hLPL (Fig. 1D). Similarly, chang-
ing amino acid residues 3 and 4 in a V5-tagged version of mLPL to the
residues found in hLPL had little effect on Mab 4-1a binding (Fig. 1E).
However, changing Ile-8 in hLPL to Ser (the residue found in mLPL) orto Thr abolished Mab 4-1a binding. Also, Mab 4-1a bound avidly to a
mLPL mutant containing Ile rather than Ser at residue 8 (Fig. 1E). In
Fig. 1D and E, Mab 4-1a binding to wild-type mLPL in CHO cell extracts
was extremely low—seemingly lower than the level of Mab 4-1a bind-
ing to highly puriﬁed mLPL in Fig. 1A. The reason for this difference is
975A. Bensadoun et al. / Biochimica et Biophysica Acta 1841 (2014) 970–976unclear but could relate to the large amount ofmLPL (350ng) loaded on
the gel in Fig. 1A.
A common LPL polymorphism, found in ~3% of the population,
changes Asp-9 toAsn (the “D9Npolymorphism”) [25–27].We suspected
that the D9N polymorphism might interfere with Mab 4-1a binding.
Indeed, Mab 4-1a did not bind to hLPL-D9N (Fig. 1F).
Mab 4-1a did not inhibit the catalytic activity of hLPL.When 30 μg of
Mab 4-1a was added to 0.25 μg of hLPL, LPL catalytic activity was not
reduced (Fig. 2A). In contrast, addingMab 5D2 reduced catalytic activity
by ~95% (Fig. 2A). When Mab 4-1a was immobilized on 96-well plates,
it captured puriﬁed hLPL and was able to detect the homodimer, as
judged by a sandwich ELISA (Fig. 2B). When the hLPL was subjected to
heat-denaturation (by placing the LPL at 45 °C), the amount of hLPL
binding to immobilized Mab 4-1a fell 6% by 5 min and ~50% by
30 min (Fig. 2C). As expected, catalytic activity was markedly inhibited
by heat-denaturation. After 5 min, hLPL catalytic activity fell by 93%
(Fig. 2C). These data suggest thatMab 4-1a bindsmore avidly to catalyt-
ically active homodimers than to the heat-denatured catalytically inac-
tive LPL monomers. The binding of hLPL to immobilized Mab 4-1a was
inﬂuenced by the concentration of NaCl. As the NaCl concentration
increased from 0.15 M to 0.75 M, the binding of Mab 4-1a increased
threefold (Fig. 2D). Mab 4-1a did not impair the binding of hLPL to
heparin-coated 96-well plates (Fig. 2E). The Kd for the equilibriumbind-
ing of Mab 4-1a for hLPL was determined to be 8.5 × 10−9 (Fig. 2F).
Binding of mLPL under the same conditions was extremely low and
just above non-speciﬁc binding (Fig. 2F), consistent with the western
blot observations (Fig. 1).
To investigate the ability ofMab 4-1a to bind to GPIHBP1-bound LPL,
CHO cells expressing an S-protein–tagged GPIHBP1 were incubated
with V5-tagged hLPL for 2 h. After washing, the cells were incubated
with Mab 4-1a for 1 h and then ﬁxed. Mab 4-1a bound avidly to
GPIHBP1-bound LPL on the surface of cells, as judged by the binding
of a ﬂuorescently labeled antibody against mouse IgG (Fig. 3). There
was no binding of Mab 4-1a to cells when hLPL was added to cells
expressing a mutant GPIHBP1 (C65S) that lacked the ability to bind
LPL [28].
Recent studies suggested that the LPL–GPIHBP1 complex is important
for the binding of TRLs to cells [5]. TRLs did not bind to nontrans-
fected cells or to GPIHBP1-transfected CHL cells; however, when the
GPIHBP1-transfected cells were pre-incubated with hLPL (therebyFig. 5.Mab 4-1a binds to hLPL in immunohistochemistry studies. Confocal microscopy images
andMab 4-1a to skeletal muscle sections from awild-typemouse (wt) and amouse expressing
followed by an Alexa568-labeled donkey anti-rat IgG. The binding of Mab 4-1a was detectedwi
avidin (green). DNA was stained with DAPI (blue).creating LPL–GPIHBP1 complexes on the cell surface), TRLs bound
avidly [5]. Mab 5D2 has been reported to interfere with the binding of
TRLs to the LPL–GPIHBP1 complex [29]. Here, we used ﬂuorescence
microscopy to compare the abilities of Mab 5D2 and Mab 4-1a to
block binding of DiI-labeled TRLs to GPIHBP1-expressing cells that had
been pre-incubated with hLPL. The results were unequivocal: Mab
4-1a had no effect on the binding of TRLs to the GPIHBP1–LPL complex
on the cell surface, whereasMab 5D2 blocked the binding of TRLs to the
GPIHBP1–LPL complex (Fig. 4).
To determine whether antibody 4-1a could be a useful tool for
immunohistochemistry studies, we assessed the ability of Mab 4-1a to
detect hLPL in tissue sections of transgenic mice that express hLPL in
skeletal muscle. Mab 4-1a bound avidly to capillaries in tissue sections
from the hLPL transgenic mice (Fig. 5), which was not surprising since
the vast majority of LPL in tissues is normally bound to GPIHBP1,
which is expressed exclusively in endothelial cells [4,30]. The binding
of Mab 4-1a to hLPL colocalized with the binding of Mab 11A12 to
GPIHBP1 (Fig. 5). In the skeletal muscle of the nontransgenic mouse,
antibody 11A12 binding to capillaries was intense but there was little
or no speciﬁc binding of Mab 4-1a (Fig. 5).4. Discussion
Nearly 60 years ago, LPL was identiﬁed as a heparin-releasable
enzyme that hydrolyzes triglycerides in TRLs [1]. More than 25 years
ago, the cDNA for LPL was cloned [31], leading to increased understand-
ing of LPL structure, physiology, and genetics, but it is still fair to say that
progress in the ﬁeld has been hampered by a paucity of useful antibody
reagents. Widely used polyclonal antibodies against LPL have been
shown to bind nonspeciﬁcally to other proteins [11], and there are
drawbacks to currently available monoclonal antibodies, all of which
bind within the carboxyl terminus of LPL. For example, Mab 5D2 blocks
catalytic activity [14], limiting its utility for certain biochemical applica-
tions, and it binds poorly and inconsistently to hLPL when it is bound to
soluble GPIHBP1. Here,we report the development and characterization
of a new monoclonal antibody against hLPL, Mab 4-1a, which binds to
the amino terminus of hLPL. Mab 4-1a binds avidly to LPL when it is
bound by GPIHBP1 on the cell surface, and, unlike Mab 5D2, does not
inhibit LPL catalytic activity.showing the binding of a mouse GPIHBP1-speciﬁc rat monoclonal antibody (Mab 11A12)
amuscle-speciﬁc hLPL transgene (hLPL-Tg). GPIHBP1 (red)was detectedwithMab 11A12
th theM.O.M. biotinylated anti-mouse IgG reagent (Vector Laboratories) followed by Fluo-
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Mab 4-1a involves residues 5–25. Because Mab 4-1a was generated in
mice, we reasoned that its epitope would involve amino acid residues
that differed in mLPL and hLPL sequences. Indeed, this was the case.
Mab 4-1a was not capable of binding hLPL when Ile-8 was changed to
Ser (the residue found inmLPL). Also, whileMab 4-1a binds very poorly
towild-typemLPL, it bound avidly to amutantmLPL inwhich Ser-8was
changed to Ile (the residue found in hLPL). Residues 3 and 4 also differed
in the human and mouse sequences, but changing those residues had
minimal effects on Mab 4-1a binding. Interestingly, Mab 4-1a binding
to hLPL was also abolished by the D9N polymorphism, which has an
allele frequency of ~3% in human populations [32,33]. Although the
D9N polymorphism is relatively uncommon, it remains an important
consideration for biochemical and immunocytochemical studies involv-
ing Mab 4-1a. When planning experiments with Mab 4-1a, it is impor-
tant to avoid the use of hLPL containing the D9N substitution.
The development ofMab 4-1a is awelcome development for the LPL
ﬁeld. It binds native LPL in immunoassays and yields extremely robust,
background-free signals on western blots. Also, it binds strongly to
GPIHBP1-bound LPL and does not interfere with LPL catalytic activity.Acknowledgements
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